Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ATR-COSF
- Development stage
- Preclinical
- Lead developer
- Azitra
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics
- Administration
- Topical
01
Overview
ATR-COSF is a preclinical-stage microbial therapy being developed by Azitra for cancer oncology support, specifically targeting skin-related adverse effects (such as skin flares or rashes) associated with cancer treatments. The drug is part of Azitra's proprietary Bio-SpE platform, which utilizes an engineered strain of *Staphylococcus epidermidis* to deliver therapeutic proteins directly to the skin microbiome. By leveraging the natural commensal properties of *S. epidermidis*, ATR-COSF aims to restore skin health and mitigate inflammation in patients undergoing systemic cancer therapies. The program is currently in the discovery and preclinical development stages.
02
Targets
KRT (Keratin, type I cuticular Ha7)
Beyond the preview
Go deeper on ATR-COSF.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ATR-COSF.